Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1988 1
1990 1
1994 1
1995 2
1996 3
1997 2
1998 1
1999 2
2000 3
2001 2
2002 2
2003 6
2004 7
2005 6
2006 4
2007 5
2008 6
2009 6
2010 15
2011 12
2012 15
2013 12
2014 12
2015 15
2016 12
2017 18
2018 12
2019 4
2020 9
2021 7
2022 5
2023 3
Text availability
Article attribute
Article type
Publication date

Search Results

182 results
Results by year
Filters applied: . Clear all
Page 1
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E, Maurice-Dror C, Calvo E, LoRusso PM, Alonso G, Rodriguez-Ruiz ME, Schoedel KB, Blum JM, Sänger B, Salcedo TW, Burm SM, Stanganello E, Verzijl D, Vascotto F, Sette A, Quinkhardt J, Plantinga TS, Toker A, van den Brink EN, Fereshteh M, Diken M, Satijn D, Kreiter S, Breij ECW, Bajaj G, Lagkadinou E, Sasser K, Türeci Ö, Forssmann U, Ahmadi T, Şahin U, Jure-Kunkel M, Melero I. Muik A, et al. Among authors: lorusso pm. Cancer Discov. 2022 May 2;12(5):1248-1265. doi: 10.1158/2159-8290.CD-21-1345. Cancer Discov. 2022. PMID: 35176764 Free PMC article. Clinical Trial.
BET inhibitors: a novel epigenetic approach.
Doroshow DB, Eder JP, LoRusso PM. Doroshow DB, et al. Among authors: lorusso pm. Ann Oncol. 2017 Aug 1;28(8):1776-1787. doi: 10.1093/annonc/mdx157. Ann Oncol. 2017. PMID: 28838216 Free article. Review.
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, Hoersch S, Smitt M, Wildiers H. Krop IE, et al. Among authors: lorusso pm. Lancet Oncol. 2017 Jun;18(6):743-754. doi: 10.1016/S1470-2045(17)30313-3. Epub 2017 May 16. Lancet Oncol. 2017. PMID: 28526538 Clinical Trial.
Vascular targeting agents.
Pilat MJ, McCormick J, LoRusso PM. Pilat MJ, et al. Among authors: lorusso pm. Curr Oncol Rep. 2004 Mar;6(2):103-10. doi: 10.1007/s11912-004-0021-6. Curr Oncol Rep. 2004. PMID: 14751087 Review.
Next-Generation Sequencing to Guide Clinical Trials.
Siu LL, Conley BA, Boerner S, LoRusso PM. Siu LL, et al. Among authors: lorusso pm. Clin Cancer Res. 2015 Oct 15;21(20):4536-44. doi: 10.1158/1078-0432.CCR-14-3215. Clin Cancer Res. 2015. PMID: 26473189 Free PMC article. Review.
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC, Wildiers H; TH3RESA study collaborators. Krop IE, et al. Among authors: lorusso pm. Lancet Oncol. 2014 Jun;15(7):689-99. doi: 10.1016/S1470-2045(14)70178-0. Epub 2014 May 2. Lancet Oncol. 2014. PMID: 24793816 Clinical Trial.
Translating clinical trials into meaningful outcomes.
LoRusso PM, Schnipper LE, Stewart DJ, Boerner SA, Averbuch SD, Wolf W. LoRusso PM, et al. Clin Cancer Res. 2010 Dec 15;16(24):5951-5. doi: 10.1158/1078-0432.CCR-10-2632. Clin Cancer Res. 2010. PMID: 21169247 Review.
182 results